Global Biodefense Market

Biodefense Market Analysis

The Global Biodefense Market size is estimated at USD 19.24 billion in 2025, and is expected to reach USD 28.43 billion by 2030, at a CAGR of 8.13% during the forecast period (2025-2030).

The biodefense market is driven by factors such as the increasing investment by governments in developed countries and rising government initiatives. Governments are introducing various initiatives to expand their research and development capabilities to meet future biological threats. For instance, in June 2023, the Biological Security Strategy of the United Kingdom aimed to protect the country from domestic and global biological risks and threats.

The government allocated EUR 1.5 billion (USD 1.6 billion) annually to support the Biological Security Strategy (BSS) in the United Kingdom in 2022. It formalizes the government’s biosecurity leadership, governance, and accountability structures to invest in the United Kingdom’s real-time biosurveillance and detection capabilities and lead internationally in establishing standards of best practice for responsible innovation. Such a high budget allocation is anticipated to fuel the growth of the market during the forecast period.

The rapid technological advancements, such as product launches and mergers by the key market players in the country, are also expected to propel market growth over the forecast period. For instance, in January 2022, Integrated Viral Protection (IVP), a Texas-based technology business, released a new portable air filtration equipment that can eliminate airborne viruses in a single pass, including sub-micron versions producing COVID-19, anthrax spores, allergens, and other dangerous respiratory triggers. The patented biodefense indoor air protection system eradicates SARS-CoV-2 (99.99%), anthrax spores (99.98%), and other airborne infections in a single pass.

The emerging trends in the biodefense market include the development of new vaccines and therapeutics, the use of nanotechnology for detection and decontamination, and the use of synthetic biology for the development of novel countermeasures. Nanoparticles can be engineered to target specific pathogens quickly, potentially accelerating the development of vaccines against emerging threats. For instance, the Journal of Neuroscience, in May 2023, stated that the ability to detect and respond to biological threats has been greatly improved through the development of nanoscale biosensors. These sensors can identify specific pathogens or toxins with remarkable speed and accuracy, offering vital tools for biodefense.

Therefore, factors such as the rising investment by governments in developed countries, such as the United States, and rapid technological advancements are expected to boost the market growth over the forecast period. However, low penetration in developing and underdeveloped countries may restrain market growth.

Biodefense Market Trends

The Anthrax Segment is Expected to Witness Healthy Growth in the Market Over the Forecast Period

Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. It occurs naturally in soil and commonly affects domestic and wild animals around the world. People can get sick with anthrax if they encounter infected animals or contaminated animal products.

The anthrax segment is fueled by factors such as the increased outbreak of anthrax among the human population, favorable government initiatives, and R&D initiatives by companies. For instance, as per the European Centre for Disease Prevention and Control (ECDC) Communicable Disease Threat Report, in July 2022, the media reported 15 human cases of cutaneous anthrax linked to an anthrax outbreak in cattle in the Sisak-Moslavina County following heavy rain in the area. Furthermore, in July 2022, the Croatian Ministry of Agriculture issued an order containing measures to prevent the emergence and spread of anthrax in the affected area. The measures include closure of affected areas, vaccination of animals, and additional prevention measures relating to humans.

The presence of competitors, mergers, acquisitions, product launches, and R&D initiatives are expected to boost the market growth. For instance, in January 2024, Emergent BioSolutions Inc. (EBS) signed a procurement contract for a maximum value of up to USD 235.8 million with the US Department of Defense (DoD) to supply its anthrax vaccine BioThrax. The vaccine is intended for use by all branches of the US military as pre-exposure prophylaxis (PrEP) for anthrax disease. This procurement contract is a five-year agreement plan with an extension option up to 2033. Additionally, in January 2023, Emergent BioSolutions Inc. received the US-FDA approval for CYFENDUS (anthrax vaccine adsorbed, adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis.

Therefore, the anthrax segment is expected to witness significant growth over the forecast period due to advancements in anthrax detection and manufacturers focusing on contract agreements and receiving approval from the authorities.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

The primary growth drivers of the biodefence market in North America are the increasing investment and initiatives by the government and rapid technological advancements in the country. For instance, as per the 2022 report from the National Association of County and City Health Officials, to address biological threats, the National Health Security Strategy (NHSS) and National Biodefense Strategy (NBS) focused on advancing the US health security enterprise through prevention, preparedness, response, recovery, and mitigation efforts to combat infectious disease and biological threats.

Additionally, in August 2023, the Department of Defense released the Biodefense Posture Review, outlining reforms aimed at the department's posture to fight and win in the face of future threats. The Biodefense Posture Review was a whole enterprise that came together during COVID-19 response efforts and, building on that collaboration, developed guidance to achieve National Defense Strategy priorities and address biological threats, especially those with strategic consequences for the US military. The high number of initiatives taken by government agencies for biodefense is expected to boost the market expansion during the forecast period.

Furthermore, as per the immediate release in August 2022 from the US Department of Health & Human Services, it facilitated an agreement between Bavarian Nordic and Grand River Aseptic Manufacturing (GRAM), a Michigan-based pharmaceutical contract manufacturer, to establish the first fill and finish line for the JYNNEOS vaccine in the United States. The vaccine is indicated for the prevention of smallpox and monkeypox. Furthermore, as per the news published in May 2022, Public Services and Procurement Canada issued a tender to purchase 500,000 doses of the Imvamune smallpox vaccine on behalf of the Public Health Agency of Canada from 2023 to 2028. The high number of people facing smallpox further raises the need for a smallpox vaccine in Canada, and it is anticipated to increase market expansion during the forecast period.

Therefore, factors such as rapid technological advancements, increasing investments and initiatives by governments, and the rising cases of smallpox in North America are expected to boost market growth over the forecast period.

Biodefense Industry Overview

The biodefence market is consolidated in nature due to the limited number of companies operating globally and regionally. The biodefense market consists of players such as Emergent BioSolutions Inc., Siga Technologies Inc., Bavarian Nordic, Nighthawk Biosciences Inc. (Elusys Therapeutics Inc.), and Ichor Medical Systems. Many companies are getting funds from governments and developing vaccines or products that are beneficial in terms of national biosecurity.

Biodefense Market Leaders

Biodefense Market News

• March 2024: Emergent BioSolutions Inc. (EBS) developed BioThrax, a vaccine approved by the US Food and Drug Administration (FDA) for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. The company is actively participating to uphold its position as the prominent manufacturer of anthrax vaccines to various organizations.
• September 2023: T2 Biosystems Inc. received the US FDA approval for its T2Biothreat Panel, which aids in detecting six high-priority biothreat pathogens in the United States. The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the T2Dx instrument, which can detect and differentiate between six biothreat pathogens in a single sample, including the organisms that cause anthrax (Bacillus anthracis), tularemia (Francisella tularensis), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), plague (Yersinia pestis), and epidemic typhus (Rickettsia prowazekii).